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(adjusted OR, 0.53; 95% CI, 0.29-0.99) were associated with amore profound protec-
tive effect than those prescribed 0.45 DDD (adjusted OR, 0.88; 95% CI, 0.52-1.51).
The longest continuous use of statins (265 days) was found to have the greatest
protective effect (adjusted OR, 0.57; 95% CI, 0.34-0.95) among all of the examined
durations. CONCLUSIONS:Any use of statins was associated with a reduced risk of
COPD exacerbation, and the protective effect was further enhanced as statins pre-
scribed more currently, at a higher average daily dose or for a longer duration. Use
of statins might be considered for preventing COPD exacerbations.
PRS9
WATERPIPE SMOKING AMONG UNIVERSITY STUDENTS IN THE UNITED
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OBJECTIVES:Waterpipe smoking has emerged as a new trend of tobacco use with
growing popularity especially among adolescents and young adults. Our objectives
were to determine the predictors of having an intention to quit waterpipe smoking
among University of Houston students who smoked awaterpipe in the pastmonth
(N276). METHODS: Cross-sectional study through an online survey in February
2011. Questions included demographics (gender, age, race/ethnicity), tobacco use
history (waterpipes, cigarettes, and cigars), perception of risk, and perceived social
acceptability of waterpipe smoking. The survey also inquired about characteristics
of tobacco waterpipe users such as the age and place of starting the waterpipe
smoking, ownership of a waterpipe, frequency and duration of waterpipe smoking
sessions, as well as willingness to quit. Descriptive statistics and chi-square anal-
yses were used to determine the frequencies and associations of participant char-
acteristics and multivariate logistic regression models were carried out to deter-
mine predictors of having an intention to quit. RESULTS:Most of the sample (83%)
reported no intention to quit. Participants who believed that waterpipe smoking
was harmful to one’s healthweremore likely to have a desire to quit (OR2.38, 95%
CI1.05-5.36). Participants with Indian or Pakistani descent were more likely to
have an intention to quit compared to white participants (OR4.74, 95% CI1.61-
13.93). Those who smoked waterpipe for more than 60 minutes were less likely to
have a desire to quit (OR0.29, 95% CI0.12-0.73). CONCLUSIONS: Findings dem-
onstrate a low level of a desire to quit among waterpipe smokers and underscore
the urgent need to develop interventions that educate waterpipe smokers about
the expected harms of continued use. This may increase the desire to quit and the
odds of a successful cessation thereafter.
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PREDICTORS OF PERSISTENT WATERPIPE SMOKING AMONG UNIVERSITY
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OBJECTIVES: Waterpipe smoking is an understudied form of tobacco use with
growing popularity among college students and amisconception of relative safety.
Our objectives were to identify predictors of persistent waterpipe smoking among
college students who have tried using a waterpipe to smoke tobacco in the past.
The participants of our study included a sample of University of Houston (UH)
students who previously used awaterpipe to smoke tobacco (N1,141).METHODS:
Cross-sectional study through a voluntary online survey in February 2011. Survey
questions included demographics (gender, age, race/ethnicity), tobacco use, risk
perception, social acceptability, and popularity of waterpipe smoking. Two out-
come variables were identified in this study: outcome 1: monthly waterpipe smok-
ing ormore versus less thanmonthly use, outcome 2:weeklywaterpipe smoking or
more versus less frequent use. Descriptive statistics and chi-square analyses were
used to determine the frequencies and associations of participant characteristics
and multivariate logistic regression models were carried out to determine predictors
of persistent waterpipe use. RESULTS: Among those who previously used a water-
pipe, approximately one fifth reported smoking a waterpipe on a monthly basis or
more, and 5% reported smoking on aweekly basis ormore. Significant predictors of
persistentwaterpipe use included:WhiteMiddle-Eastern ethnicity, IndianAsian or
Pakistani Asian ethnicity, past 30-day cigar use, ownership of a waterpipe, believ-
ing waterpipe smoking was cool, and longer than 30 minutes waterpipe smoking
sessions. Those who believed that waterpipe smoking was harmful to one’s health
and those who thought government should evaluate the safety before selling the
waterpipes were less likely to become persistent users. CONCLUSIONS: Findings of
this study highlight the importance of developing interventions that address the
predictors identified. Educational programs that explain the potential harms of
waterpipe smoking and modify the cool image associated may be effective in pre-
venting the spread of this rapidly emerging health hazard.
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OBJECTIVES: Palivizumab given monthly prior to and throughout the RSV season
reduces incidence of RSV hospitalization (RSV-H) in premature infants, infants
with chronic lung disease of prematurity (CLDP), and children with hemodynami-
cally significant congenital heart disease (CHD). This study determines the impact
of non-compliance with palivizumab dosing and risk of RSV-H among Medicaid-
insured infants. METHODS: Infants with prematurity [34 weeks’ gestational age
(wGA)], CLDP and/or CHD born and discharged between May 1 and September 30
whoreceived1doseofpalivizumabduring theirfirstRSVseason (October1 -April 30)
were identified retrospectively in Medicaid claims data from 12 states. Palivizumab
compliance (first dose by November 30,5 consecutive doses during the RSV season,
and no gaps 35 days between consecutive doses) was evaluated across 6 seasons
(2003-2009). The percentage of infants with in-season RSV-H was calculated for non-
compliantandcompliant cohorts. Logistic regressionofRSV-Hwasperformed, adjust-
ing for non-compliance, wGA, birthweight, comorbidities, and other demographic/
clinical characteristics. RESULTS: A total of 8443 high-risk infants received 1 dose
of palivizumab. Approximately 67% of all infants were non-compliant. The per-
centage of infants with RSV-H was significantly higher among non-compliant vs.
compliant infants (12.0% vs. 7.4%, P0.001). In the logistic regression model, non-
compliant compared to compliant infants had a 1.31 (95% CI 1.18, 1.46) increased
odds of RSV-H, and odds were also higher for males, rural residents, capitated
healthplan members, infants who required neonatal intensive care at birth, gesta-
tional age 32 weeks or unknown (vs. 33-34 weeks), age 3 months at season
onset, and comorbidities (including CLDP/CHD) or emergency room/hospitaliza-
tion prior to first dose (all P0.001). CONCLUSIONS: Non-compliance with palivi-
zumab was common and significantly increased the risk of RSV-H in this Medicaid
population. Intervention strategies are needed to improve palivizumab adminis-
tration among Medicaid infants prior to and throughout the RSV season.
RESPIRATORY-RELATED DISORDERS – Cost Studies
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BUDGET IMPACT ANALYSIS OF TIOTROPIUM BROMIDE VERSUS IPRATROPIUM
BROMIDE ON THE TOP OF STANDARD THERAPY IN THE TREATMENT OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN RUSSIAN
FEDERATION
Kulikov A, Komarov I
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: To estimate the budget impact of the inclusion of tiotropiumbromide
compared to ipratropium bromide on the top of standard COPD treatment scheme
with long-acting bronchodilators.METHODS: The one-year budget impact analysis
was conducted. Direct expenses associatedwith COPD exacerbations and resulting
follow-up costs were calculated using general tariff agreement of Russian obliga-
tory insurance system and official national statistics. For reference, accepted ex-
change rate was 1 EUR 40 RUB. RESULTS: Tiotropium bromide inclusion into the
standard COPD therapy provided cost saving benefits compared with inclusion of
ipratropium bromide in the COPD standard therapy scheme. Total costs of COPD
therapy were approximately 259,730 RUB (6,493 EUR) per patient in tiotropium
bromide group and 266,887 RUB (6,672 EUR) per patient in ipratropium bromide
groupwithin one year. Treatment of COPD using standard therapywith tiotropium
bromide inclusion compared to onewith ipratropiumbromide leads to cost savings
of 7,157 RUB (179 EUR) per patient-year. CONCLUSIONS: The results of budget
impact analysis illustrate that including tiotropium bromide into the standard
therapy of COPD instead of ipratropium bromide has potential to reduce Russian
health care system total costs for COPD treatment.
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Chronic obstructive pulmonary disease (COPD) is an increasing cause of morbi-
mortality in adults worldwide with a heavy economic burden on society. The in-
troduction of indacaterol, a neweffective long acting beta agonist, justifies a budget
impact analysis from the Colombian Health-Care System perspective.
OBJECTIVES: To develop a budget impact analysis, for five years, of the indacaterol
introduction in the Colombian Health-Care System.METHODS:Using the perspec-
tive of the Colombian Health-care System, we designed a budget impact model to
compare costs with and without the introduction of indacaterol for patients with
COPD GOLD stages II-III-IV. Clinical data and prevalence were obtained from pub-
lished literature. Basal maintenance treatment costs were calculated according to
GOLD guidelines consumption patterns and exacerbation costs were collected
from university hospital registries. A probabilistic Montecarlo sensitivity analysis
was performed. RESULTS: Total annual net costs (year 1-year 5) for the scenario
without indacaterol were: USD $40.123.556, $40.591.558, $41.056.575, $ 1.531.189
and $42.011.289. In the indacaterol scenario net costs were: $ 41.743.333, $
38.772.406, $ 38.862.224, $ 38.838.471 and $ 38.797.766. CONCLUSIONS:Under these
assumptions the progressive introduction of indacaterol in Colombian health care
system implies budgetary savings.
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TREATMENTS FOR COMMUNITY ACQUIRED PNEUMONIA REQUIRING
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OLDER, FROM PRIVATE PERSPECTIVE IN BRAZIL
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OBJECTIVES: The private health care system in Brazil currently assists 47,008,888
individuals in Brazil. This study has the objective of evaluating the cost-effective-
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ness of azithromycin 500mg/day QD and clarithromycin 1g/day BID for the treat-
ment of CAP for immunocompetent individuals age 65 and older from the private
healthcare perspective in Brazil.METHODS: A decision-tree model, built based on
the following health states: death, cure and discontinuing due to adverse events
(phlebitis, diarrhea, infusion reaction which would lead to switching the antibiot-
ics). Risks and length of treatment were obtained from the literature and prices
were retrieved from the Brazilian Hierarchic Classification of Medical Procedures
(CBHPM 4th edition - 2005) and public databases. Resource Utilization (exams,
procedures andmaterials) were gathered based on the latest clinical guidelines for
CAP defined by the Brazilian Society of Pneumology. The time horizon was defined
as one year. Effectiveness was expressed as life years gained (LYG). Values were
expressed in 2011 USD. First order probabilistic sensitivity analysis was carried by
Monte Carlo simulation of 10,000 iterations considering the range of values for the
lengths of treatment in a normal distribution. RESULTS: The simulation consider-
ing 10,000 iterations showed the following values for azithromycin and clarithro-
mycin respectively: Total LYG [9,640 vs. 8,840]; average costs per treatment
[USD863.76 vs. USD1,384.15]; average cost-effectiveness ratio [USD896.04/LYG vs.
USD1,566.18/LYG], representing a cost saving of USD 670.14/LYG for azithromycin.
Considering 100,000 cases of pneumonia hospitalizations for adults age 65, the total
savings for the incorporationofazithromycinwouldbeapproximatelyUSD52.072.571.
CONCLUSIONS: In this analysis, azithromycin presented the greatest effectiveness
diminishing costs, by reducing mortality and treatment discontinuation due to
adverse events, from the Brazilian private health care system’s perspective.
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OBJECTIVES: According to Brazilian public databases (DATASUS), community ac-
quired pneumonia (CAP) requiring hospitalization for individuals of age 65 have a
mortality relative risk increase of 4.05 when compared to the average rate of
younger ages. This study has the objective of evaluating the cost-effectiveness of
azithromycin 500mg/day QD and clarithromycin 1g/day BID for the treatment of
CAP for immunocompetent individuals age 65 and older from the public healthcare
perspective in Brazil.METHODS: A decision-tree model, built based on the follow-
ing health states: death, cure and discontinuing due to adverse events (phlebitis,
diarrhea, infusion reaction which would lead to switching the antibiotics). Risks
and length of treatment were obtained from the published literature and acquisi-
tion costs were retrieved from Brazilian public databases (Banco de Preços em
Saúde and SIGTAP - Sistema de Gerenciamento da Tabela de Procedimentos, Me-
dicamentos e OPMdo SUS). Resource utilization (exams, procedures andmaterials)
were gathered based on the latest clinical guidelines for CAP defined by the Brazil-
ian Society of Pneumology. The timehorizonwas defined as one year. Effectiveness
was expressed as life years gained (LYG). Values were expressed in 2011 USD. First
order probabilistic sensitivity analysis was carried by Monte Carlo simulation of
10,000 iterations considering the range of values for the lengths of treatment in a
normal distribution. RESULTS: Simulation considering 10,000 iterations showed
the following values for azithromycin and clarithromycin respectively: Total LYG
[9,640vs.8,840]; average costs per treatment [USD614.11vs.USD618.15]; average
cost-effectiveness ratio [USD637.07/LYGvs.USD699.23/LYG], representing a cost
saving per patient of USD62.17/LYG for azithromycin. Considering 180,851 cases of
pneumonia hospitalizations for adults age 65 registered at public hospitals in
Brazil(2010), the overall estimated savings for the incorporation of azithromycin
would be approximately USD730,561.15. CONCLUSIONS: In this analysis, azithro-
mycin presented the greatest effectiveness diminishing costs, by reducing mortal-
ity and treatment discontinuation due to adverse events.
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OBJECTIVES: To estimate the economic burden associated with acute exacerba-
tions of chronic obstructive pulmonary disease (COPD) in Tianjin, China.
METHODS: Data from the Tianjin Urban Employee Basic Medical Insurance
(UEBMI) database (2003-2007), including inpatient claims for medical services and
prescription drugs from 30% random sample of enrollees, were used. Acute exac-
erbationwas defined as aCOPDepisode leading to hospitalization. Hospitalizations
of adult patientswith primary diagnosis of COPDanddischarge dates between 2003
and 2007 were selected and the latest COPD hospitalization for each patient was
selected to estimate healthcare utilization and costs associated with COPD acute
exacerbation. All costs were estimated in 2007 U.S. dollars using the Medical Ser-
vice Consumer Price Index (CPI) in China and an exchange rate of 7.598 Chinese
Yuan to 1 USD in 2007. RESULTS: A total of 1321 COPD patients with acute exacer-
bations were identified, with a mean age of 71.1 years and 41.3% female. Approxi-
mately 38.4% of all patients had at least one complication, 21.3% had cor pulmo-
nale, 19.8% had pneumonia, 11.0% had congestive heart failure, and 4.9% had
bronchiectasis. About 58.2% hospitalizations occurred in tier-3 hospitals, 36.2% in
tier-2 hospitals and 5.6% in tier-1 hospitals. The mean length of stay was 16.8 days
per hospitalization. About 92.9% patients received antiathmatic, 75.2% received
expectorant, and 24.6% received antitussive during hospitalization. Themean total
cost per acute exacerbation/hospitalization was $1323 with 74.1% covered by
UEBMI and 25.9% by patients. Medication costs accounted for 56.3% of the total
inpatient costs. Examination costs and bed costs accounted for 16.4% and 4.5%,
respectively. CONCLUSIONS: Complications of COPD are common among patients
with COPD exacerbations. The majority of patients with COPD exacerbations are
treated in tier-3 hospitals. COPD exacerbations incur high health care utilization
and costs. Medication costs account for the majority of the costs associated with
exacerbations.
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DIRECT INCREMENTAL COSTS OF CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD) AND ASTHMA IN THE UNITED STATES
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OBJECTIVES: To estimate the national prevalence and the direct incremental costs
of Chronic Obstructive Pulmonary Disease (COPD) and asthma using the 2007Med-
ical Expenditure Panel Survey (MEPS) data. METHODS: This was a retrospective
study of patient records identified using ICD-9-CM diagnosis and procedure codes
for principal diagnosis of COPD (491.0, 492.0, 496.0) and asthma (493.0, 493.1, 493.2)
from the 2007 MEPS data. The main independent variable was the presence or
absence of either COPD or asthma. Age, gender, race, income, insurance status,
marital status and region were selected as covariates. The dependent variables
were total health care, office-based, outpatient, inpatient, emergency room, and
prescription expenditures. Descriptive statistics and regression analyses were uti-
lized to generate prevalence data, total mean health care expenditures, and signif-
icant predictors for individuals with COPD and asthma. RESULTS: The national
prevalence of COPD and asthma in 2007 was estimated at 1.3 million and 28.3
million, respectively. Among individuals with COPD, the estimated total direct
incremental health care expenditures per person was $1739.27 with a national
estimate of $2.2 billion. Among individuals with asthma, the estimated total direct
incremental health care expenditure per person was $2133.83 with a national es-
timate of $60 billion. The largest cost category for COPD was office-based expendi-
tures ($610.55) followed by prescription expenditures ($347.88). For asthma, the
largest cost categories were prescription expenditures ($760.72) followed by inpa-
tient expenditures ($617.23). Age, gender, region, insurance and marital status
were significant predictors for health care expenditures in COPD and asthma.
CONCLUSIONS: This study highlights the socio-demographic disparities in terms
of prevalence and provides national estimates on health care expenditures among
individuals with COPD and asthma. These estimates can serve as a guide for policy
makers in the formulation of health care policies on screening, treatment guide-
lines, and identification of high-risk population for COPD and asthma.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading
cause of death in the world and remains a disease with substantial residual mor-
bidity and cost burden. Current evidence-based guidelines focus attention on
achieving and maintaining disease stability and reducing the incidence of exacer-
bations as important management targets. Few disease-based models exist for
COPD. Our objective was to develop a dynamic, natural history model that reflects
progression of COPD, events and treatments that characterize its management.
METHODS:We developed an Excel-based Markov model with 4 health states rep-
resenting the Global Burden of Lung Disease (GOLD) disease severity classification.
Within each GOLD stage, we model stable disease with three levels of COPD exac-
erbation. We include 2 health states for end-stage treatments (lung transplant and
lung volume reduction surgery [LVRS]) as well as death. Data to populate progres-
sion comes from published clinical studies and lung function data collected within
the Framingham Heart Study. The model simulates disease progression, severity
and event- and stage specific mortality, exacerbations and quality-adjusted sur-
vival over a lifetime. Cost parameters reflect 2010 US resource use. RESULTS: We
calibratedmodel progression andmortality using data from the 5-year LungHealth
Study. Initiating a cohort simulationwith a 60 year old, 79.2% of the cohort remains
in GOLD stage I and II after 5 years. The simulation produces average annual costs
of $970, $5,700, $13,000, and $13,700for GOLD stages I to IV, respectively. Only a
small fraction (2%) of the cohort progresses to transplant and LVRS. Over 91% of
the cohort survived through the 5-year simulation, with a background mortality
rate for 60-year-olds at almost 1% annually. CONCLUSIONS: A natural history
model of COPD can be useful for estimating disease progression, costs and the
impact of new technologies. Future research is needed to validate the model pre-
dictions.
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OBJECTIVES: To estimate COPD exacerbation incidence rates, related costs, and
predictors among managed care patients treated for chronic bronchitis (CB).
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